|Articles|December 26, 2019

Clinics Encourage PrEP Use in Pregnant and Postpartum African Women

A new study out of Africa demonstrates that maternal-child clinics may act as a one-stop shop for both pregnancy and postpartum concerns and HIV protection.

One of the most vulnerable populations in areas of sub-Saharan Africa that experience high rates of HIV is pregnant and postpartum women. Studies have shown an incidence rate in this group roughly equal to that of women who work in the sex trade, and the risk is not mitigated even if women have partners who currently are HIV negative or if women are having less frequent sex because of impending or recent childbirth.

Concerned about this elevated risk to both mothers and babies, a team of investigators from the University of Washington in Seattle teamed up with the Kenyan Kisumu County Department of Health to create a program known as PrIYA, for PrEP [pre-exposure prophylaxis] Implementation for Young Women and Adolescents. The goal was to allow women who visited any of 16 different maternal-child health centers to receive a behavioral assessment designed to provide information about HIV risk, learn about PrEP, and obtain a prescription for PrEP, if desired.

Between November 2017 and June 2018, more than 9300 women or adolescents from the age of 15 up who visited a clinic received a behavioral assessment and were asked if they wanted to start taking PrEP. Two thousand and thirty women, or 21.7% of the total, agreed to take PrEP. They were more likely to be younger (the median age was 24), with partners who had HIV or whose HIV status was unknown. Of those women who began PrEP, 38.7 continued using it after 1 month. However, in women who knew their partners were HIV positive, the continuation rate after 1 month shot up to 68%.

“Our results show that maternal and child health clinics can be an effective platform for PrEP delivery,” the authors wrote in the discussion section of their report. “Maternal and child health clinics currently deliver prevention of mother-to-child HIV transmission services including HIV testing and retesting, and can thus identify women at risk for HIV who could benefit from PrEP.” Retesting is an important part of HIV prevention, the authors noted, explaining that HIV risk can shift over time, making it imperative that women have access to PrEP “in periods of increased vulnerability.”

While women may be concerned about their HIV risk if their partners’ HIV status is positive or unknown, many African women feel disempowered to take preventive measures. According to the authors, condoms are not commonly used by women who are pregnant or have recently given birth, and male partners often are not willing to consider them. “PrEP offers protection while allowing time for women to encourage their partners to get tested and initiate treatment if HIV-infected,” according to the authors.

The authors noted that, in a different study, women mentioned being particularly concerned about HIV infection during pregnancy because they were having less sex with their male partners, who might then seek sex outside of the relationship. Other research suggests the possibility of biological changes that make pregnancy and the postpartum period particularly risky times for HIV transmission. Considering the difficulty some women have convincing their male partners to get tested for HIV or use condoms, the ability to take PrEP discreetly may give women the peace of mind they need during this time.


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths.¹ The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.